Description
Vildagliptin 50 mg & Metformin Hydrochloride 500 mg fixed-dose combination tablet is used for the management of type 2 diabetes mellitus when diet, exercise, and monotherapy are not sufficient to control blood glucose. It combines Vildagliptin, a DPP-4 inhibitor, with Metformin, a first-line biguanide oral hypoglycemic agent. Together, they provide complementary mechanisms to improve glycemic control without causing significant weight gain or hypoglycemia.
Mechanism of Action:
- Vildagliptin inhibits the enzyme DPP-4, which breaks down incretin hormones (GLP-1 and GIP). These hormones increase insulin secretion and suppress glucagon release in a glucose-dependent manner, improving postprandial glucose control.
- Metformin reduces hepatic glucose production (gluconeogenesis), increases insulin sensitivity, and improves peripheral glucose uptake and utilization. It also helps with weight neutrality or modest loss.
Uses: Type 2 Diabetes Mellitus:
- As second-line therapy when monotherapy with metformin or vildagliptin is inadequate
- As initial combination therapy in selected patients
- To improve glycemic control alongside lifestyle modifications (diet and exercise)
-
